CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER (cefoxitin sodium) by B. Braun is 12. Approved for lower respiratory tract infections, including pneumonia, lung abscess and 33 more indications. First approved in 2006.
Drug data last refreshed 19h ago · AI intelligence enriched 2w ago
Cefoxitin sodium is a second-generation cephalosporin antibiotic supplied in a duplex container with dextrose for IV administration. It treats a broad spectrum of infections including respiratory tract, urinary tract, intra-abdominal, gynecological, bone/joint, and skin infections caused by gram-positive, gram-negative, and anaerobic bacteria. The drug acts as a bactericidal agent by inhibiting bacterial cell wall synthesis and retains activity against some beta-lactamase-producing organisms.
Product is approaching loss of exclusivity with moderate competitive pressure (30%), signaling potential team consolidation and shift toward lifecycle extension or product transition strategies.
12.1 Mechanism of Action Cefoxitin is an antibacterial drug [ ] . 12.2 Pharmacodynamics The pharmacodynamic properties of cefoxitin are unknown. 12.3 Pharmacokinetics Absorption Following an intravenous dose of 1 gram, serum concentrations were 110 mcg/mL at 5 minutes, declining to less than 1…
Worked on CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER at B. Braun? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on this product offers stability in a mature, well-established antibiotic franchise with broad hospital usage, but limited growth opportunities given LOE approach. Career value lies in lifecycle management expertise, hospital formulary negotiations, cost-containment strategies, and potential transition to next-generation cephalosporin programs within the portfolio.